FRAZER, Pa., Nov. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc., today announced that Standard and Poor’s will add Cephalon to the S&P 500 Index after the close of trading on Friday, November 14. Cephalon has been listed in the S&P MidCap 400 Index.
“We are honored to be recognized among the foremost companies in the United States,” said Frank Baldino, Jr., Ph.D., Chairman and CEO. “This distinction is a result of the talented and dedicated employees who are committed to physicians and the patients they treat. Over the past twenty-one years, we have built an enduring, diversified company and we are very proud of the fact that our products have helped millions of patients around the world.”
About the S&P 500
Widely regarded as the best single gauge of the U.S. equities market, this world-renowned index includes 500 leading companies in leading industries of the U.S. economy.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company’s headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company’s European headquarters are located in Maisons-Alfort, France.
The company’s proprietary products in the United States include: TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
CONTACT: Media, Sheryl Williams, +1-610-738-6493, swilliam@cephalon.com,
or Investors, Robert (Chip) Merritt, +1-610-738-6376,
cmerritt@cephalon.com, both of Cephalon, Inc.
Web site: http://www.cephalon.com/
